Japan’s Ministry Of Health, Labour And Welfare Approves Novocure's Optune Pax To Treat Adults With Unresectable Locally Advanced Pancreatic Cancer

Novocure (Nasdaq: NVCR) has received approval from Japan’s Ministry of Health, Labour and Welfare for its Optune Pax® device, which is intended for the treatment of adults with unresectable locally advanced pancreatic cancer. The treatment will be used in conjunction with gemcitabine and nab-paclitaxel.